

Übersicht zu Forschungsprojekten DZL-assoziierter Arbeitsgruppen zu COVID-19 (Coronavirus SARS-CoV-2)

Programm	Thema	Beteiligter DZL-Standort	Weitere Informationen
DZL 3.0	CAPNETZ - German Competence Network for Community Acquired Pneumonia (CAP) as an Associated DZL Institution	ARCN, BREATH, CPC-M, TLRC, UGMLC	CAPNETZ - German Competence Network for Community Acquired Pneumonia
DZL 3.0	Dissecting novel mechanisms of pathogen recognition and host response in pneumonia	BREATH, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 3.0	Lung regeneration and stem cell heterogeneity after acute lung injury	BREATH, CPC-M, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 3.0	“PROGRESS-Representative” CAP patient cohort	ARCN, BREATH, CPC-M, TLRC, UGMLC	PROGRESS - Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis
DZL 3.0	Resolving heterogeneity of clinical ARDS phenotypes at different levels in DZL cohorts	BREATH, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 3.0	Targeting recently identified pathways of lung injury and resolution for improved outcome	BREATH, CPC-M, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 2.0 / DZL 3.0	A longitudinal study on identifying risk factors for contracting COVID-19 and prediction of recovery trajectory in Chronic Lung Disease patients across age using combined multi-omics and clinical deep phenotyping data pre- and post-COVID exposure	CPC-M	DZL-Krankheitsbereich Chronisch Obstruktive Lungenerkrankungen (COPD)
DZL 2.0 / DZL 3.0 + Partner	Analyse bildgebender Verfahren zur Diagnostik und klinischen Einordnung einer durch SARS-CoV-2 verursachten Pneumonie (COVID-19 Pneumonie)	TLRC	DZL-Standort TLRC

Übersicht zu Forschungsprojekten DZL-assoziierter Arbeitsgruppen zu COVID-19 (Coronavirus SARS-CoV-2)

Programm	Thema	Beteiligter DZL-Standort	Weitere Informationen
DZL 2.0 / DZL 3.0	ARDS-Registers an der Medizinischen Hochschule Hannover (MHH)	BREATH	Medizinische Hochschule Hannover
DZL 2.0 / DZL 3.0	Effects of cigarette smoking on COVID-19 susceptibility	CPC-M	DZL-Standort CPC-M
DZL 2.0 / DZL 3.0 / DFG / BfR	Inhibition of coronavirus replication in a human organotypic culture system: Potential inhibitors of coronavirus replication with emphasis on immunophilin blockers cyclosporin A, FK506, and non-immunosuppressive derivatives using patient-derived human bronchial epithelial cells at the air-liquid interface (CPC-M bioArchive) to develop novel anti-coronaviral treatment measures	CPC-M	DZL-Standort CPC-M
DZL 2.0 / DZL 3.0 + Partner	Risk prediction and therapy monitoring of severe clinical courses in hospitalized patients with SARS-CoV-2-infection / COVID-19	TLRC	DZL-Standort TLRC
DZL 2.0 / DZL 3.0	SARS-CoV-2 gene signature in CLD - Deep, high-quality single cell sequencing data from lung epithelial cells from healthy young and aged individuals as well as individuals with CLDs to identify expression of potential SARS-CoV-2 receptors/Co-receptors and signaling mediators in subpopulations across the age spectrum as well as in patients with CLDs	CPC-M	DZL-Standort CPC-M
DZL 2.0	Cell-specific in-vivo/vitro dissection and network biology of lung inflammation - initiation/control/ termination/resolution during infection	BREATH, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 2.0	Phase II/III clinical trials of inhalation based adjunctive ALI therapies (GM-CSF; FGF10) and antibiotics in COPD exacerbation – signature analysis in large patient cohorts to identify novel biomarkers	ARCN, BREATH, CPC-M, TLRC, UGMLC	CAPNETZ - German Competence Network for Community Acquired Pneumonia

Übersicht zu Forschungsprojekten DZL-assoziierter Arbeitsgruppen zu COVID-19 (Coronavirus SARS-CoV-2)

Programm	Thema	Beteiligter DZL-Standort	Weitere Informationen
	<i>Fortsetzung</i>		PROGRESS - Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis GI-HOPE@Clinicaltrials.gov
DZL 2.0	Preclinical/clinical development of local-progenitor/stem cell-based ALI repair strategies	BREATH, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 2.0	Preclinical evaluation of targeted and spatially/temporally restricted interventions to attenuate alveolar injury and protect lung barrier function while preserving host defense and repair capacity	BREATH, TLRC, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 2.0	Systematic analyses of GM-CSF-induced host defense and repair signatures in alveolar and circulating innate immune cells from patients included in the GI-HOPE study (GI-HOPE-SIG / ALI clinical flagship project)	BREATH, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen GI-HOPE@Clinicaltrials.gov
DZL 2.0	Targeting regeneration programs and cellular interactions in lung stem cell niches for repair after infection-induced injury (ALI translational flagship project)	BREATH, UGMLC	DZL-Krankheitsbereich Pneumonie & Akutes Lungenversagen
DZL 2.0	Identification of novel hydrophobic allergens and functional lipids and their effects on barrier crossing and cell function; testing of novel hydrophobic allergens/lipids and potential biomarkers for clinical	CPC-M	DZL-Krankheitsbereich Asthma & Allergien

Übersicht zu Forschungsprojekten DZL-assoziierter Arbeitsgruppen zu COVID-19 (Coronavirus SARS-CoV-2)

Programm	Thema	Beteiligter DZL-Standort	Weitere Informationen
	relevance in experimental disease models for the development of different asthma phenotypes		
WHO	WHO SOLIDARITY Trial, Koordinierung und Durchführung der deutschen Beteiligung der WHO Studie "Solidarity" gemäß den WHO Protokollen	BREATH, UGMLC	WHO Solidarity Trial
DFG (KFO)	Klinischen Forschergruppe KFO309 „Virus-Induced Lung Injury: Pathobiology and Novel Therapeutic Strategies“ (Prof. Susanne Herold, Gießen)	UGMLC	KFO309 „Virus-Induced Lung Injury: Pathobiology and Novel Therapeutic Strategies“
DFG (Exzellenzstrategie)	Exzellenzcluster Resist - Resolving Infection Susceptibility – Teilprojekte • Aging Immune System • Senior Individuals (Aufbau einer Kohorte gesunder Älterer) • Neutralisierende Antikörpern gegen SARS-CoV2	BREATH	Exzellenzcluster Resist - Resolving Infection Susceptibility
UGLC	Novel CO2 elimination techniques in patients with severe COVID-19-induced ARDS and hypercapnia (CO2-FILTER)	UGMLC	ECCO2R@Clinicaltrials.gov
UGLC / DZL 2.0 / DZL 3.0	GI-COVID, „GM-CSF Inhalation zur Verhinderung des akuten Lungenversagens bei COVID-19-Pneumonie“	UGMLC	<i>In Vorbereitung</i>
Hoffmann-La Roche Ltd.	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of Tocilizumab in patients with severe Covid-10 pneumonia	BREATH	COVACTA@Clinicaltrials.gov
LEOSS	European multi-center cohort study to identify independent predictors of outcome in patients with SARS-CoV-2.	ARCN, BREATH, CPC-M, TLRC, UGMLC	LEOSS